Journal
ACS APPLIED MATERIALS & INTERFACES
Volume 13, Issue 15, Pages 17158-17173Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acsami.1c03640
Keywords
melittin; nanocarrier; drug delivery; cancer therapy; immunotherapy
Funding
- National Natural Science Foundation of China [82022040, 81874233]
- Key International Cooperation Project of Hubei Province [2020BHB021]
- China Postdoctoral Science Foundation [2020M682431]
Ask authors/readers for more resources
Melittin (MLT) has shown promising anticancer effects due to its broad lytic effects, but challenges such as tissue distribution, hemolysis, metabolism, and specificity hinder its translation. Emerging drug delivery strategies could address these issues and improve treatment efficacy, while opportunities for MLT-based cancer immunotherapy are also being explored.
Melittin (MLT) has been studied preclinically as an anticancer agent based on its broad lytic effects in multiple tumor types. However, unsatisfactory tissue distribution, hemolysis, rapid metabolism, and limited specificity are critical obstacles that limit the translation of MLT. Emerging drug delivery strategies hold promise for targeting, controlled drug release, reduced side effects, and ultimately improved treatment efficiency. In this review, we discuss recent advances in the use of diverse carriers to deliver MLT, with an emphasis on the design and mechanisms of action. We further outline the opportunities for MLT-based cancer immunotherapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available